Related Experiment Videos
Current Drug Options for Raising HDL Cholesterol
Richard L Dunbar1, Daniel J Rader
1University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia, PHI building, Suite 351, 39th and Market Streets, Philadelphia, PA 19104, USA. richard.dunbar@uphs.upenn.edu.
Current Treatment Options in Cardiovascular Medicine
|May 26, 2005
Summary
Raising high-density lipoprotein cholesterol (HDLC) lacks definitive event-based trial data. Therapy decisions for low HDLC focus on cardiovascular risk, often involving statins and potentially niacin or fibrates for high-risk individuals.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Low high-density lipoprotein cholesterol (HDLC) is linked to cardiovascular risk, but evidence for HDLC-raising therapy benefits is limited.
- Current dyslipidemia guidelines prioritize low-density lipoprotein cholesterol (LDLC) and non-HDLC targets.
- The decision to target low HDLC is based on individual cardiovascular event risk assessment.
Purpose of the Study:
- To review the current evidence and clinical considerations for high-density lipoprotein (HDL)-raising therapy in patients with low HDLC.
- To outline therapeutic strategies for managing low HDLC in various cardiovascular risk groups.
Main Methods:
- Review of existing clinical guidelines and evidence regarding HDLC management.
- Analysis of pharmacologic approaches for increasing HDLC levels.
- Discussion of risk stratification for guiding HDLC-targeted therapy.
Main Results:
- Statins are primary therapy for LDLC and non-HDLC goals, often benefiting patients with low HDLC.
- Niacin or fibrates may be added to statins for significant HDLC elevation in high-risk patients.
- No formal HDLC goals exist, but target levels are generally >40 mg/dL (men) and >50 mg/dL (women).
Conclusions:
- Pharmacologic intervention to raise HDLC is primarily considered for high-risk patients (e.g., established vascular disease, diabetes, high Framingham score).
- Therapy for moderate-risk patients with low HDLC requires careful individualization.
- Further event-based trials are needed to definitively establish the benefit of HDL-raising therapies.